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This paper conceptualizes the supply chain of innovation of a company as its supply chain not related to
physical goods exchanges but to R&D commodities exchanges. R&D commodities, being the outcomes of
research activities, are for example patents, technologies, research services, studies, projects, etc. Spe-
ciﬁcally, we focus on the relationship between the activities of purchasing/selling R&D commodities and
the propensity of the ﬁrm to develop new products; we examine how the position of the ﬁrm within its
innovation network moderates this relationship. The empirical setting of the research consists of a cross-
sectional dataset of 544 biopharmaceutical companies that have signed 1772 R&D agreements in the
years 2006–2010. We ﬁnd ﬁrstly, evidence of the supply chain of innovation (as a natural evolution of the
well-acknowledged dual-market model of the biopharmaceutical industry). Secondly, we ﬁnd that the
relational embeddedness, coming from innovation network, inﬂuences the effect of purchasing and
selling R&D commodities on new product development. Supporting our theoretical predictions, this
paper offers contributions to the scientiﬁc literature on supply chain relationships in new product de-
velopment.
& 2015 Elsevier Ltd. All rights reserved.1. Introduction
The movement of ﬁrms towards opening their new product
development (NPD) process, for example by involving and in-
tegrating with suppliers, has rapidly increased since the 1990s
(Harland, 1996). For this reason the operations and supply chain
management academic community, in the last two decades, has
deeply investigated collaboration models in NPD, such as supplier
involvement (Johnsen, 2009) and customer integration (Flynn
et al., 2010).
However, besides collaborating with suppliers and customers
during the NPD process, companies did also start using external
competencies and exploiting internal knowledge in the form of
R&D commodities by directly purchasing and selling them from
and to external parties. External parties include universities, re-
search centers, other companies, but also suppliers and buyers
(Pilkington, 1999). R&D commodities are R&D products or activ-
ities that can be purchased and/or commercialized, such as R&D
services, projects, patents, technologies and licenses.
While the operations management literature has put much
effort in exploring the effects of collaboration with traditionalola),suppliers and buyers on NPD performance, much less attention
has been paid to analyse the effect on NPD of purchasing and
selling R&D commodities to and from external parties. However, a
lot of empirical works have demonstrated that these more and
more adopted practices strongly inﬂuences the innovation per-
formance of the ﬁrm (Mazzola et al., 2012; West et al., 2014). For
this reason, when designing the NPD process, managers should
take into account precise considerations about the consequences
of R&D purchasing and selling on the outcome of this process.
To ﬁll this gap, in this paper we explore the relationship be-
tween R&D purchasing/selling activities and the ﬁrm's NPD, and
we conceptualize the Supply Chain of Innovation (SCoI), as the
supply chain not related to the material ﬂow but to the R&D
commodities ﬂow. We, indeed, observe that the propensity of a
company towards purchasing and selling of R&D brings the com-
pany to position itself along the SCoI. Positioning downstream
makes the company closer to the ﬁnal market, and thus it will be
stimulated more than others to develop new marketable products.
Conversely, positioning upstream makes it closer to the R&D
market, and thus the company will be stimulated more than
others to develop and sell R&D commodities instead of end-con-
sumer products. In other words, in this paper we use the SCoI lens
to understand and interpret the consequences of R&D purchasing
and selling in terms of NPD performance.
Actually, besides being positioned within the SCoI, the com-
pany is also surrounded and embedded in a more complex web of
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just buys and sells R&D commodities in order to acquire or exploit
knowledge, but also signs alliances and other bilateral agreements
with other companies for similar purposes. From the complex
network of relationships surrounding each company, the company
itself can beneﬁt in terms of resources and information acquisition
(Granovetter, 1992). Speciﬁcally, following the recent expansion in
research incorporating different strategic management perspec-
tives in the ﬁeld of operations and supply chain management (Mol,
2003; Krause et al., 2007; Meehan and Bryde, 2014), we absorb
social capital view in studying the effect of “being part of a net-
work” on the NPD process. We consider that the quality of the
information that a company gains from its network depends on its
relational embeddedness in the network, i.e. the quality of re-
lationships that the ego ﬁrm builds with its partners (Granovetter,
1992; Uzzi, 1996; Meehan and Bryde, 2014). There is a wide con-
sensus among researchers that the ﬁrm’s embeddedness and its
position in a network of relations matter for its NPD (Soh, 2003;
Pérez-Luño et al., 2011; Mazzola et al., 2015). For this reason, in
this paper we also explore whether relational embeddedness en-
hances or reduces the effect of R&D purchasing and selling on
NPD.
The empirical setting of this study consists of the total set of
agreements signed by biotech companies listed in BioWorld data-
base 2006–2010, where biotech company means both pure bio-
technological, and biopharmaceutical. We use this setting in order
to ﬁnd evidence of the existence of the SCoI and of the phenom-
enon of ﬁrms' positioning along it. Indeed, the advent of bio-
technology as a new paradigm changed the shape of the classical
pharmaceutical industry into a dual market structure (Pisano,
1991; Chiesa and Toletti, 2004; Narayana et al., 2014). Biotech
ﬁrms are focusing on producing and commercializing different
R&D commodities, and thus are positioning themselves along the
SCoI.2. The supply chain of innovation
The supply chain management literature has deeply in-
vestigated the role of collaborating with suppliers and buyers in
the NPD process. For example, Twigg (1998) examines the re-
lationships between a vehicle manufacturer and six key suppliers
which contribute to the ﬁnal design of products; the author terms
‘design chain’ the interaction of design information between each
supplier and customer. In fact, several collaboration modes with
suppliers and customers in NPD have been analyzed: supplier
innovation generation (Jean et al., 2012); early supplier involve-
ment (Koufteros et al., 2005; Johnsen, 2009); supplier involvement
and investment (Song et al., 2011); supplier integration (Petersen
et al., 2005; Ettlie and Pavlou, 2006; Swink et al., 2007); supplier
development (Krause et al., 2007); and customer involvement
(Flynn et al., 2010).
To achieve the same objectives of collaboration for NPD, in the
last ten years companies started purchasing and selling R&D
commodities in many industries: for example, this behavior has
been identiﬁed as one of the main trends in the biopharmaceutical
industry (Chiesa and Toletti, 2004; Birch, 2008). This phenomenon
lets us argue that, mostly in high-tech industries, a new kind of
supply chain is emerging: namely, the supply chain of innovation
(SCoI). We deﬁne the SCoI of a company as the supply chain not
related to the material ﬂow but to the innovation ﬂow. Physical
goods are replaced by patents and the material ﬂow supply chain
is replaced by the innovation-ﬂow supply chain.
To make our research context clear, it is essential to specify the
difference between material-ﬂow supply chain (SCoM) and in-
novation-ﬂow supply chain (SCoI).According to Christopher (1992) a SCoM is a chain (or network)
of organizations that are involved in the different transformation
processes that add value to one speciﬁc product and that bring it
to the hand of the ultimate consumer. For instance ‘[…] a shirt
manufacturer is a part of a supply chain that extends upstream
through the weavers of fabrics to the manufacturers of ﬁbers, and
downstream through distributors and retailers to the ﬁnal consumer’
(Christopher, 1992, p. 12). And indeed, it is usually referred to as
the supply chain of a product.
Contrarily, the SCoI is a chain (or network) of organizations
involved in the innovation process and not in the transformation
(manufacturing) process. For this reason, it is better to con-
ceptualize the SCoI as a chain which is not product-centered, but
company-centered. It is the network of businesses including
buyers (and buyers’ buyers) and suppliers (and suppliers’ suppli-
ers) involved in the innovation process of a given company, the
focal company. This deﬁnition is also in line with one of the major
use of the term ‘supply chain management’ as indicated by (Har-
land, 1996, p. 64): ‘There are four main uses of the term ‘supply chain
management’: […] Thirdly, the management of a chain of businesses
including a supplier, a supplier’s suppliers, a customer and a custo-
mer’s customer, and so on’.
To illustrate an example of SCoI, consider the following buyer–
supplier relationships that Amgen, a large biopharmaceutical
company, was recently involved in. We found that Amgen li-
censed-out 13 molecules to Takeda Pharmaceutical Co. Ltd. Con-
versely, Amgen has licensed-in the ‘Cabily’ patent family from
Genentech Inc., which in turn has purchased research services on
multiple drug targets from Sareum Holdings. Of course, these
supply chain relationships do not necessarily refer to the same
molecule, but they refer to R&D purchasing and selling related to
Amgen (independently from speciﬁc molecule) with its suppliers
and buyers. We also found many other companies (biotech, bio-
pharmaceutical, big-pharma, universities, clinical research orga-
nizations, etc.) that were involved in the supply chain of Amgen.
To make clear the difference between the SCoM and the SCoI
we summarize the main characteristics of these two types of
supply chain in Table 1.
The typical actors involved in the SCoM are suppliers, manu-
facturers, distributors, and others, which buy from each other (or
sell to) physical goods. The objects of each commercial transaction
are raw or semi-manufactured parts and components that, thus,
ﬂow from upstream to downstream along the supply chain. Con-
trarily, the actors in the SCoI are research centers or high tech
companies which exchange R&D commodities. A supplier in the
SCoM, for example, could be a high-tech company with a large
body of knowledge (and patent stock) which also sells its R&D
commodities to its customers. From the customer side, a company
could buy both physical materials and R&D commodities from the
same supplier.
The R&D commodity (e.g. a research service, project, patent,
technology, or license) is the object of the commercial transaction
and the terms ‘supplier’ or ‘buyer’ are meant as provider or user of
an R&D commodity. The ﬁnal product (meant as ﬁnal result) of the
SCoM is the product on the hand of the customer. The ﬁnal pro-
duct of the SCoI is, instead, the ﬁnal outcome of the innovation
process, for example a new developed product which has not been
industrialized yet.
The typical buyer–supplier relationships in the SCoM are
transactional, unless products are co-produced and/or co-dis-
tributed. However, while the main goal of the SCoM is trans-
forming raw materials into ﬁnished products, its actors are also
involved in the new product development process. To this pur-
pose, bilateral agreements (supplier involvement, customer in-
tegration, etc.) among ﬁrms are necessary to support innovative
activities as they can facilitate complex coordination beyond what
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SCoM, buyer–supplier relationships for NPD are mostly relational
oriented. Besides bilateral agreements, the set of relationships the
company enters for NPD purposes, is also enriched by transac-
tional agreements that the ﬁrm signs with actors, which are not
necessarily involved in the SCoM, for acquiring new knowledge.
For example Amgen has licensed-in the ‘Cabily’ patent family from
Genentech Inc. which is not a supplier of Amgen in the SCoM. The
set of these unilateral and mostly transactional oriented “buyer–
supplier relationships” constitutes the SCoI.
From a different perspective, the SCoI can be seen as a subset of
the complex network of relationships constituting the innovation
network in which the company is embedded. It includes only
speciﬁc kinds of relationships, i.e. those transactional that are re-
lated to the purchase and selling of R&D commodities. Neither
vertical bilateral collaborations (such as early supplier involve-
ment or customer integration) nor horizontal bilateral collabora-
tions (such as R&D joint venture, co-patenting or co-development)
are included since they do not explicitly concern a pure buyer–
supplier commercial transaction.
As an example, the lower part of Fig. 1 models the numerous
actors participating in the process of innovation in the biotech
industry. They include biotech ﬁrms, biopharmaceutical ﬁrms, big-
pharma ﬁrms, research institutes, universities, CRO, CMO, biotech
platforms, etc. Also, different typologies of relations can be found,
such as alliances, licensing agreements, research collaborations,
production, marketing and distribution agreements, R&D out-
sourcing, R&D joint ventures, co-patenting, etc. The upper part of
Fig. 1 models the SCoI, and thus only reports transactional re-
lationships of the type buyer–supplier.
The relational embeddedness of a company within the whole
innovation network has been conceptualized by Koka and Prescott
(2002) as the dimension of social capital that yields different in-
formation beneﬁts in the form of information richness, i.e. the
quality and nature of information that a ﬁrm can access through its
relationships. The level of relational embeddedness of the com-
pany within the network is strictly related to its position within
the complex network structure (Moran, 2005). The network
structure is shaped by the intricate webs of interﬁrm relationships,
such as buyer–supplier relationships, strategic alliances, joint
ventures, R&D agreements, licensing agreements, joint member-
ships in industry associations, and every form of collaboration. The
network created by all these inter-ﬁrm relationships (not just SCoI
relationships) is a conduit for information.
The nature of this information could be beneﬁcial for the ef-
fectiveness of R&D purchasing and selling relationships within the
SCoI. This is why, besides the position of the company within the
SCoI, in this study we also take into account the whole innovation
network structure where the company is embedded.3. Conceptual model
In order to develop our conceptual model (Fig. 2) we combine
SCoI and innovation network views. Firstly, we explain the inﬂu-
ence of purchasing and selling R&D on the NPD process. Secondly,
we consider how the characteristics of the innovation network in
which the ﬁrm is embedded may affect the beneﬁts or dis-
advantages of purchasing and selling R&D, due to the information
richness the company gains from its relationships.
3.1. SCoI and NPD process: the role of purchasing and selling R&D
The impact of collaboration practices in the NPD with suppliers,
customers and other SCoM actors has been very much investigated
in the operations and supply chain management literature
Fig. 1. The supply chain of innovation as a subset of the innovation network.
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the impact of supplier involvement on technical performance of
new products. Supplier integration has been largely found to be
related to product development performance (Ragatz et al., 2002;
Petersen et al., 2005; Koufteros et al., 2007; Humphreys et al.,
2007). Conversely, customer integration has been found to be re-
lated to customer satisfaction, both directly (Homburg and Stock,
2004) and indirectly, through its relationship to product devel-
opment and innovation (Koufteros et al., 2005; Song and Bene-
detto 2008).
The positive effect of collaboration practices, as well as colla-
borative competences, on the NPD process has thus been largely
demonstrated in the supply chain management literature on NPD
(Mishra and Shah, 2009) and has been justiﬁed in terms of the
value creation and knowledge sharing arising from the relational
nature of these bilateral agreements (Menguc et al., 2014).
In fact, besides collaborating with SCoM partners, a ﬁrm could
acquire external knowledge and technology by in-licensing and/or
purchasing R&D services, projects, intellectual properties, and
patents by other ﬁrms (Tsai and Wang, 2009; Chiaroni et al., 2010;
Mazzola et al., 2012). These practices are transactional in their
nature.Fig. 2. The conceSo, the same kind of beneﬁts resulting from collaboration
practices in SCoM could also be achieved by less costly transac-
tional relationships in SCoI, at least in those industries where a
market of R&D exists, such as in the high-tech industries. When
the market offers a high number of companies that sell R&D
commodities, then acquiring external knowledge by signing
transactional agreements becomes a possible practice which is
also less costly to coordinate respect to achieving the same ob-
jective by collaborating. For instance, in the biotech industry it is
very common that companies share knowledge and create value
by purchasing test assays, pre-clinical programs, licenses for using
technologies and platforms, etc.
Relying on external, already-developed knowledge and tech-
nologies enables a ﬁrm to improve its NPD process since it de-
creases, for example, the time to develop the product, and im-
proves its pre-emptive advantage, or limits competitors’ ﬁrst-
mover advantages (Tsai and Wang, 2009). Given that in high-tech
industry external knowledge and technologies acquisition is
achieved by SCoI transactional agreements, and being R&D pur-
chasing surely a way to acquire external knowledge, we state the
following hypothesis:ptual model.
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modities is positively related to ﬁrms' new product development.
The advent of biotechnology as a new paradigm changed the
shape of the classical pharmaceutical industry into a dual market
structure (Pisano, 1991). Conventional big pharmaceutical ﬁrms
have increasingly become dependent on small and medium bio-
technology companies for new discoveries in the upstream.
Without inﬂow of science-based knowledge, big-pharma compa-
nies face strategic challenges in competing in the global market
(Powell et al., 1996; Sabatier et al., 2010). On the other hand, small
and medium biotechnology ﬁrms in the upstream, by licensing-
out or by forming joint ventures, can commercialize their dis-
coveries without further developing those discoveries to a ﬁnal
product. In sum, it is well recognized that companies belonging to
the downstream side of the Pisano’s dual market structure develop
more new products than those belonging to the upstream side.
In this paper, we instead argue that things are not black and
white. We hypothesized that there is not just a dual market
structure where companies behave in two different ways. Alter-
natively we think that there is a gray scale between upstream and
downstream due to the existence of a complex supply chain of
innovation. There are not companies that just focus on developing
and selling R&D (upstream side of Pisano’s dual structure) and on
buying and exploiting R&D by industrializing and commercializing
end-consumer products (downstream side), but there is a con-
tinuum in the propensity of a company on selling and purchasing
R&D. Such a propensity determines the position of the company
along the SCoI.
The more the company is specialising in developing R&D
commodities and selling them in order to generate additional
revenues, the more this behavior makes the R&D selling business
its main business. This, in turn, will consolidate the upstream
positioning of the company in the SCoI and will distance it from
the stage of developing consumer-marketable products.
We thus state our second hypothesis:
H2. In a supply chain of innovation the selling of R&D commod-
ities is negatively related to ﬁrms’ new product development.
3.2. SCoI and NPD process: the moderating role of relational
embeddedness
The information beneﬁts available to a ﬁrm differ based on its
network structure, its overall experience of relationships and its
history with current partners. Relational embeddedness has been
associated with richer access to information for the ego ﬁrm
(Meehan and Bryde, 2014). For example, being a member of a
clique (a sub-network in which any company is directly connected
to any other company in the sub-network) increases the relational
embeddedness of the company within the network by enhancing
the connectivity density of members within the clique (Wasser-
man and Faust, 1994). This ensures that information introduced
into the clique will quickly reach other companies in the clique.
Being relational embedded also enhances the ﬁdelity in the in-
formation received and increases the formation of trust and norms
among companies (Schilling and Phelps, 2007). Being relational
embedded allows companies to gather superior information on
each other by reducing in this way the information asymmetry
that increases the likelihood of opportunistic behavior.
Also, the information richness that a company gets from its
whole innovation network positively inﬂuence its knowledge-ab-
sorptive capacity (Cohen and Levinthal, 1990), and may increase
the opportunities for learning and for developing skills in mana-
ging the new product development process. Given that SCoI
practices, such as purchase and selling of R&D commodities, allowknowledge to ﬂow in and ﬂow out, the information richness
coming from the whole network (not just from the SCoI) needs to
be fully considered when studying the effects of such practices on
new product development. For instance, by creating routines
among partners, the partner ﬁrms develop shared schemas, and
better understanding of the knowledge ﬂow coming from having
purchased a speciﬁc R&D commodity. Also, the information rich-
ness may leverage knowledge use and increase knowledge-ex-
ploitation opportunities. Firms more relational embeddeded more
likely are involved in a high number of R&D projects: this surely
proliferates the opportunities for exploiting the knowledge arising
from having purchased a speciﬁc R&D commodity.
Therefore we expect that relational embeddedness, which
boosts information richness, enhances the positive effect of pur-
chasing R&D commodities on new product development.
Summing up, this leads to our third hypothesis as follows:
H3. In a supply chain of innovation the impact of purchasing R&D
commodities on ﬁrms’ new product development is moderated by
its relational embeddedness in the whole innovation network: the
higher the relational embeddedness, the greater the beneﬁt from
purchasing R&D.
Going back to our conceptualisation of the SCoI, we consider
now those ﬁrms that re-focus their core business in selling R&D
commodities, and position themselves along the supply chain
closer to upstream stages. We have already discussed how, in the
SCoI, R&D suppliers license out or commercialize their discoveries,
without further contributing to the development of those dis-
coveries into ﬁnal compounds. Once again, this specialization
brings interesting results in terms of economic-ﬁnancial perfor-
mance while bringing negative effects in terms of the develop-
ment of ﬁnal products.
Now we argue that, even in the case in which the company
focuses on producing and selling R&D commodities, information
richness deserves to be fully considered when studying the effects
of such R&D selling practices on NPD. Indeed, the information
richness that a company gets from its innovation network posi-
tively affects its performance. Koka and Prescott (2002) and Malik
(2012) identify a number of reasons underlying the positive link
between relational embeddedness and the performance of ﬁrms.
Being as the development and selling of R&D commodities is the
main business of a supplier within the SCoI, the information
richness positively inﬂuences its performance in conducting such
business. This, in turns, enforces the company business position
upstream in the SCoI, and better distinguishes its role with respect
to that of a ﬁnal drug developer. Therefore, we expect that this
network characteristic, which boosts information richness, am-
pliﬁes the negative effect of selling R&D commodities on the de-
velopment of new products.
We thus state our fourth hypothesis:
H4. The impact of selling R&D commodities on ﬁrms’ new product
development is moderated by the relational embeddedness: the
higher the relational embeddedness, the greater the damage from
selling R&D.4. Research method
4.1. Sample and data
We chose the biotechnology industry as the research setting
because it is characterised by a high level of innovation processes
(Rothaermel and Deeds, 2004; Sabatier et al., 2010), and because
we found evidence of the existence of SCoI within this industry.
We gathered data from multiple sources about new products,
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characteristics. We obtained data on inter-ﬁrm relations through
BioWorld database, an online information service providing daily
news and analysis, stock indices, company coverage, regulatory
and patent reports, and other biotechnology information. Among
the different sections available on BioWorld database, we ex-
clusively collected data about relations between biotech compa-
nies in the years 2006–2010, where biotech company means both
pure biotechnological and biopharmaceutical. The full dataset in-
cludes 1772 agreements among 1842 biotechnological ﬁrms.
From this dataset, we then selected only public companies,
speciﬁcally 544 ﬁrms, to ensure the availability and reliability of
ﬁrm-attribute data. This approach is quite common in this kind of
study since it does not affect the sample through selection bias
(e.g. Stuart et al., 2007; Malik, 2012). Thus, we collected data about
new products, patenting and ﬁrm-attributes of this selected
sample. The SCoI and the whole innovation network data of each
of these 544 ﬁrms are computed by considering their relationships
with all the companies included in the full dataset. We retrieved
data on new product development from the ‘biotech products’
section of BioWorld database. The patenting data are retrieved
from the US Patents Ofﬁce database. Finally, we collected ﬁrm-
attribute data from the companies’ annual reports.
4.2. Variable deﬁnition and operationalisation
4.2.1. Dependent variable
The dependent variable (New products) measures the total
number of new biopharmaceutical products introduced in the
market throughout 2010–2012. To assess different lag speciﬁca-
tions between SCoI practices, relational embeddedness (Re-
lational_Emb) and new products, we adopt a moving window ap-
proach (Bae and Gargiulo, 2004; Salman and Saives, 2005); fol-
lowing this approach, the dependent variable is calculated con-
sidering the three years succeeding the ﬁve-year biotech-biotech
agreements’ observations, that is the period 2010–2012. Thus, we
have computed the biopharmaceutical products marketed from
the end of 2010 to the end of 2012.
4.2.2. Independent variables
As concerns the SCoI, we consider the two following ex-
planatory variables: R&D purchasing and R&D selling. We measure
the variable R&D purchasing by counting how many times each
company purchases R&D commodities such as R&D services, test
assays, pre-clinical programs, licenses, and so on. We measure the
variable R&D selling by counting how many times each company
sells R&D commodities. These two measures are calculated be-
tween 2006 and 2010, by using agreements’ data collected from
the BioWorld database. For example, we selected the agreement
signed by Gruenenthal GmbH and Forest Laboratories, in which
the latter has licensed-in a patent from the former. The descriptionTable 2
Descriptive statistics and correlation matrix.
Mean Std. Dev. Min. Max. (1) (2)
1. New products 0.18 0.71 0 11 1.00
2. Patent stock 1.68 1.84 0 8.11 0.29 1.00
3. Pipeline 1.10 0.53 0 1.94 0.21 0.11
4. Age 23.14 26.94 0 358 0.07 0.26
5. R&D investment 2.69 1.78 0 9 0.33 0.57
6. Industry 0.62 0.48 0 1 0.01 0.03
7. Nationality 0.37 0.48 0 1 0.07 0.12
8. R&D purchasing 0.90 1.68 0 23 0.11 0.15
9. R&D selling 0.82 1.59 0 22 0.02 0.15
10. Relational_Emb 0.06 0.43 0 8 0.18 0.12of the agreement provided in BioWorld is:
Licensing agreement for phase 2 small-molecule analgesic GRT
6005 and follow on compound GRT 6006 to Forest Laboratories.
Forest will pay an up-front fee, milestones and royalties in ex-
change for U.S. and Canadian rights..
With regard to the innovation network, we consider the ex-
planatory variable: relational embeddedness, measured through
the number of cliques the company is embedded in. We adopt this
measure for relational embeddedness because being part of a cli-
que increases connectivity density of partners. Indeed, the multi-
ple pathways between ﬁrms ensure that information will quickly
reach all the companies in the clique, enhance the ﬁdelity in the
information received, and increase the trust in each other (Was-
serman and Faust, 1994; Rowley et al., 2005; Vanhaverbeke et al.,
2009). We measured this number by using UCINET VI (Borgatti
et al., 2002), a network analysis program that computes
network variables using dyadic data. Speciﬁcally, in line with the
prior research (Rowley et al., 2005), we used the
‘Network4Subgroups4Cliques’ procedure implemented in UCI-
NET VI to detect the presence of relevant cliques; this procedure
facilitates the measuring of how many cliques each company is
embedded in. To calculate this network measure we ﬁrst collected
BioWorld data into an inter-ﬁrm relationships matrix, containing
all the agreements established among the 1842 biotech ﬁrms
throughout 2006–2010. We recorded each agreement in ﬁve bin-
ary nxn (one per observed year) adjacency matrixes, At, where nt is
the number of ﬁrms present in the year t. For each matrix, the
term Atij is set to 1 if company i and j had signed an agreement in
year t, otherwise 0. Then, we activated the UCINET procedure (as
described above) to compute the clique value for each company
for each year. Finally we computed the average clique for each
company throughout the years.
4.2.3. Control variables
We include six control variables to remove any potential con-
founding correlation of other factors on the ﬁrms' new product
development.
We control for patent stock, since it reﬂects the level of tech-
nological capital, absorptive capacity and R&D know-how of a
company (Vanhaverbeke et al., 2009). Speciﬁcally, we measure the
natural logarithm of the number of ﬁrm patents obtained in the
thirty years prior to 2010. Following previous researches, we add
the number of products in the pipeline as control since they re-
present accumulated stocks of knowledge (DeCarolis and Deeds,
1999). The ﬁrms’ product pipeline is measured by the natural
logarithm of the number of products companies had in each of the
signiﬁcant stages of the pipeline in 2010. Next, the age of a com-
pany is also included as control variable (Vanhaverbeke et al.,
2009). We operationalize ﬁrms’ age as the number of years from
the date of founding to 2010. Furthermore, we include the natural(3) (4) (5) (6) (7) (8) (9) (10) VIF
1.59
1.00 1.11
0.09 1.00 1.12
0.25 0.22 1.00 1.62
0.12 0.15 0.08 1.00 1.07
0.08 0.07 0.08 0.09 1.00 1.06
0.06 0.02 0.10 0.01 0.01 1.00 1.10
0.10 0.01 0.12 0.10 0.01 0.26 1.00 1.68
0.09 0.04 0.12 0.10 0.05 0.23 0.61 1.00 1.65
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proxy of ﬁrms’ R&D investments (Ahuja, 2000; Bae and Gargiulo,
2004). We include an industry dummy variable to indicate whe-
ther a company is a biotechnological or a biopharmaceutical
(Vanhaverbeke et al., 2009). Finally, we consider the nationality of
the ﬁrm as control (Ahuja, 2000; Phelps, 2010; Vanhaverbeke
et al., 2009).5. Results
The dependent variable is a count variable that takes only non-
negative integer values, that is the number of new biotechnolo-
gical products a ﬁrm successfully marketed 2010–2012. A Poisson
regression approach provides a natural model for such typology of
data (Hausman et al., 1984). However, a Poisson regression as-
sumes that the mean and variance of the count variable are equal.
This assumption is likely to be violated since over-dispersion
usually occurs in new product count data. Over-dispersion re-
quires the use of a negative binomial estimation (Un et al., 2010);
therefore, we test our hypotheses by using a negative binomial
regression.
Table 2 provides the descriptive statistics and the correlations
between all the variables for the 544 public companies in the se-
lected sample. The correlation coefﬁcients between the in-
dependent variables are quite low. Also we calculate, and report in
the last column of Table 2, the variance inﬂation factor (VIF) value,
a more advanced measure of multicollinearity than simple corre-
lations (Stevens, 1992); the VIF values are below the critical level,
indicating that the explanatory variables can simultaneously be
included in the models (Gujarati, 1995).
Descriptive statistics ﬁrstly show that the number of new de-
veloped product is quite low in our sample (on average 0.18 new
products in three years 2010–2012). Fig. 3 shows that most of the
companies - 484 over 544 - launched zero new products in the
market (a) and some of them also had zero products even in their
pipeline at 2010 (b), while on average the companies in our
sample had 2.43 products in the pipeline.
This is exactly what we expected, given that our sample is
made by biotechnological and biopharmaceutical companies that
are more focused on R&D activities than pure pharmaceutical
companies (‘[…] Bio-pharma companies may not have a new drug
marketed every year’, Mazzola et al., 2015, p. 112). Given that on
average it takes 15 years for a new product to be developed, i.e.
each product stays in the pipelines 15 years on average, and for
every 10,000 compound screened, only one drug will be approved
(Rothaermel and Deeds, 2004), the results in Fig. 3(a) and
(b) clearly show that biotech and biopharma companies are notFig. 3. Frequencies of new developed products in the years 20focused in developing new products. Conversely there are more
focused in doing research as it is further conﬁrmed by the high
number of patents obtained by each company of our sample in the
thirty years prior to 2010, on average equal to 56.26.
Also, descriptive statistics show that the average number of
R&D purchasing and R&D selling agreements in the ﬁve years is
quite low (respectively 0.90 and 0.82). Fig. 4 shows the frequencies
of these agreements within our sample. On average each company
signs less than one purchasing or selling agreement in ﬁve years.
Of course this does not exclude that companies meanwhile sign
other kinds of R&D agreements, for example alliances and bilateral
agreements, for innovation purposes. As we already mentioned,
the supply chain of innovation is just a part that can be extracted
from the whole innovation network. In fact, in our sample the
average number of R&D agreements in the ﬁve years is 2.6 agree-
ments (we calculated this number by taking into account the
whole innovation network). Also, one should consider that on
average an R&D agreement typically last for more than a year. For
example Rosenkopf and Schilling (2007) assumed that R&D re-
lationships would last for three years, consistently with the em-
pirical work of Phelps (2003).
Table 3 provides an overview of the results of the negative
binomial analysis. We focus on the full model (model 4) to ex-
amine the theoretical expectations addressed earlier, but also
provide the basic model with only control variables (model 1), the
model that includes explanatory variable related to the SCoI
(model 2), and a model including explanatory variable related to
the innovation network (model 3). To avoid a multicollinearity
problem, we mean-center the independent variables of the re-
gression model (Danese and Romano, 2013). Then, we also calcu-
late for the two interaction variables the VIF test; the two values of
R&D purchasingRelational_Emb’s VIF (3.01) and R&D sell-
ingRelational_Emb’s VIF (2.99) are both quite well below the
critical level, as also is the Mean VIF of the whole model (1.79).
This indicates that the interaction variables can simultaneously be
included in model 4 (Jaccard and Turrisi, 2003).
Looking at the results from model 1, we observe that all the
coefﬁcients are stable over all the models, indicating the robust-
ness of the results. Next, we ﬁnd a positive and signiﬁcant relation
between pipeline and ﬁrms' new products, meaning that biotech
companies that have a greater number of products along their
pipeline tend to develop more new products. By contrast, the
negative coefﬁcient for age would indicate that newly-established
ﬁrms might have a slight advantage in developing new bio-
technological products. The coefﬁcient of R&D investment is po-
sitive, and signiﬁcantly related to ﬁrms’ new products, meaning
that the increasing in R&D investments results in increasing in-
novative output. There are also signiﬁcant differences between10–2012 (a) and new products in the pipeline in 2010 (b).
Fig. 4. Frequencies of R&D purchasing (a) and selling (b) in 2006–2010.
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are biopharmaceutical. Nationality variable is negative and sig-
niﬁcant in all the models; thus, as expected, US ﬁrms develop
more biotech products. Finally, patent stock is not signiﬁcant.
Model 2 introduces R&D purchasing and selling as explanatory
variables. The coefﬁcients of the R&D purchasing and selling
variables have the expected signs, but only R&D purchasing is
signiﬁcant. In line with H1, the coefﬁcient R&D purchasing is po-
sitive, implying that companies that purchase more R&D com-
modities also develop more new biotech products. Summing up,
the ﬁrst results corroborate H1 but do not support H2.
Model 3 introduces the network structure characteristic, rela-
tional embeddedness: we ﬁnd that relational embeddedness is
signiﬁcant and positively related to NPD.Table 3
Results of negative binomial regression model.
Dep. var.: new products
Model 1
Controls
Patent stock 0.177n
(0.0794)
Pipeline 1.724nnn
(0.357)
Age 0.0124†
(0.00632)
R&D investment 0.415nnn
(0.0923)
Industry 0.524†
(0.291)
Nationality 0.596†
(0.314)
Explanatory variables
R&D purchasing
R&D selling
Relational_Emb
R&D purchasingRelational_Emb
R&D sellingRelational_Emb
Constant 5.962nnn
(0.600)
Num. obs. 544
Wald χ2 110.96nnn
Log-likelihood 197.80
Standard errors in parentheses. †p o 0.10, np o 0.05, nnnp o 0.001.Model 4 introduces the pairwise interaction terms between the
three explanatory variables to test hypotheses H3 and H4. We
expect a positive interaction effect between purchasing R&D
commodities and relational embeddedness (H3), and a negative
interaction effect between selling R&D commodities and relational
embeddedness (H4). As Table 3 shows, both the interaction terms
are signiﬁcant and the signs as predicted. So while H3 is fully
conﬁrmed, the same cannot be said for H4. Indeed, although the
effect of the product variable (R&D sellingRelational_Emb) is
signiﬁcant and negative, because the main effect of the variable
R&D selling revealed to be not signiﬁcant (H2 not supported), re-
lational embeddedness cannot be considered as a moderator in
this case.
In addition, as also suggested by Jaccard and Turrisi (2003), toModel 2 Model 3 Model 4
0.130 0.122 0.0891
(0.0814) (0.0809) (0.0735)
1.643nnn 1.592nnn 1.422nnn
(0.350) (0.343) (0.279)
0.0135n 0.0126n 0.0132n
(0.00645) (0.00615) (0.00525)
0.466nnn 0.444nnn 0.505nnn
(0.0949) (0.0934) (0.0880)
0.491† 0.609n 0.793n
(0.294) (0.300) (0.325)
0.616n 0.652n 0.556†
(0.311) (0.305) (0.331)
0.123n 0.116n 0.0251
(0.0572) (0.0562) (0.0785)
0.0221 0.101 0.0313
(0.0693) (0.0793) (0.0882)
0.408† 0.593n
(0.220) (0.257)
0.120n
(0.0535)
0.150†
(0.0845)
6.009nnn 5.898nnn 6.002nnn
(0.600) (0.587) (0.507)
544 544 544
115.16nnn 118.54nnn 126.74nnn
195.70 194.01 189.91
Fig. 5. Interaction R&D purchasing x Relational_Emb (Predicted probability).
Fig. 6. Interaction R&D selling x Relational_Emb (Predicted probability).
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analysis of the moderating effects (Figs. 5 and 6).
Fig. 5 plots the effect of the interaction on predicted values of
new products, of R&D purchasing and relational embeddedness. In
line with Danese and Romano (2013) we set two values of rela-
tional embeddedness, i.e. ‘high’ and ‘low’ respectively, as one
standard deviation above and below the mean. Also, in line with
Schilling and Phelps (2007), the end points of the lines are cal-
culated at one standard deviation below and above the mean of
R&D purchasing. The plot suggests that a high level of R&D pur-
chasing should be accompanied by a high level of relational em-
beddedness, if the objective is to accelerate the effect of R&D
purchasing on the propensity to develop new products.
Fig. 6 plots the effect of R&D selling on predicted values of new
product for the same values of relational embeddedness as before.
The plot shows how combining a high degree of R&D selling and a
high level of relational embeddedness decreases the propensity to
develop new products.6. Discussion and conclusions
This study was motivated by important limitations of existing
research on R&D purchasing and selling practices and new product
development. The literature has indeed largely ignored, on one
hand, that companies, by selling and purchasing R&Dcommodities, are positioning themselves along the SCoI and, on
the other hand, the potential inﬂuence of social capital on the
effectiveness of those practices.
By explicitly conceptualizing the supply chain at the innovation
level, this study brings to the attention of managers the need to
consider the SCoI as something different from both the SCoM and
the whole innovation network (see Table 1 and Fig. 1).
In fact, this study was inspired by our conceptualisation of the
SCoI. While nowadays we are assisting the establishment of supply
chains of R&D, in which companies position themselves as sup-
pliers of speciﬁc R&D commodities (we found empirical evidence
for this), the literature on supply chain collaboration for NPD deals
with buyer–supplier relationships that are mostly relational-or-
iented. Conversely, it does not explicitly consider the buyer–sup-
plier agreements of kind R&D purchasing/selling because, al-
though they may be used to achieve the same goal (knowledge
acquisition and value creation), they are not real collaboration
agreements, being mostly transactional-oriented.
We know that, especially in high tech industries, the NPD
process is not accomplished by the company alone but by the
company together with a number of partners. These partners and
the relationships that the focal company establishes with them
depend on the way in which they contribute to the NPD process.
To this purpose, we identify up to three different kinds of net-
works surrounding the company in which the partners can belong
to: the SCoM, the SCoI, and the innovation network. The nature,
the goals, the structures, and the relationships within these three
networks can be different. However, during the NPD process the
focal company may acquire external knowledge from all the three
networks above mentioned, so they all contribute to the NPD
process. For example, in order to develop a new product the focal
company can collaborate with a supplier of components (SCoM)
by, for example, involving it in the early stages of product design;
but the company can also license-in a patent from a supplier of
R&D (SCoI) to include an already developed technology in the new
product; ﬁnally, the company can sign an R&D joint-venture
agreement with an overseas partner (innovation network) to co-
develop and commercialize the new product.
The conclusion is that, when designing the NPD process,
managers have to take into account precise considerations not just
about their company’s collaborations with SCoM partners (the
literature on supply chain management is reach of studies on re-
lational-oriented collaboration with suppliers and customers for
NPD) but also about the relationships of their company with its
SCoI members and, meanwhile, they do not have to neglect the
effect of relational embeddedness coming from the whole in-
novation network. These are indeed the three different systems
which contribute to the NPD process and this is why they should
be considered as a whole.
This study addresses these limitations and also uses social ca-
pital theory (Coleman, 1988; Burt, 1998; Adler and Kwon, 2002;
Koka and Prescott, 2002; Wu, 2008; Malik, 2012) to consider how
the relational embeddedness (as driver of information richness)
within the whole innovation network inﬂuences SCoI relation-
ships’ effectiveness. In doing so, this study moves beyond the dual-
market structure perspective typically used in biotech industry
research. The results are quite in line with the predictions of the
theoretical model, and we discuss them in the following subsec-
tions where we also identify implications for research and
practice.
6.1. Positioning within the SCoI
We predicted (H1) a linear and positive effect of purchasing
R&D commodities on new products, and we found evidence of
this. This result shows that, in biotech industry, opening the
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test assays or preclinical programs (but also licensing-in patents or
technological platforms), stimulates the company to develop and
market new ﬁnal products. Consistent with prior works on open
innovation (Chesbrough, 2003; West and Bogers, 2013; West et al.,
2014), this ﬁnding suggests that relying on external already-de-
veloped knowledge and technology enables a ﬁrm to improve its
innovation performance, since the ﬁrm uses suppliers' systems
and mechanisms that facilitate the access to new and complex
knowledge (Laursen and Salter, 2006). For example, when Amgen,
a biotech company, licensed-in from Genentech (another biotech
company) their ‘Cabilly’ patent family for producing im-
munoglobulin, it gained access to new knowledge that allowed it
to develop new antibodies. In our sample, Amgen has a high
number of R&D purchasing agreements and a high number of new
developed, approved and marketed products. By purchasing R&D
commodities, the ﬁrm positions itself downstream in the supply
chain, closer to the ﬁnal market, and thus it is more stimulated
than others to develop new marketable molecules and drugs.
We predicted (H2) a linear and negative effect of selling R&D
commodities on new products but we did not ﬁnd evidence of
this. This result would suggest that, in biotech industry, selling and
marketing own research services (but also licensing-out proper
patents or technological platforms), does not affect the company’s
propensity to develop and market new ﬁnal products, by either
inhibiting or leveraging. Probably, the adoption of these practices
inﬂuences the numbers of developed patents or another innova-
tion outcome. However, we did not consider these other innova-
tion outcomes in this study.
These ﬁrst results have important implications in practice. In
the biotech industry, companies increasingly tend to externally
purchase different typologies of R&D commodities. In con-
sequence, more and more other companies are specialising in
supplying and selling those commodities. Thus managers should
make precise decisions about the position of their company within
the SCoI. If they position downstream, the purchasing of R&D
commodities has positive effects on the development of new
products. Conversely, if they position upstream, the licensing-out
and the commercialization of own discoveries, while generating
additional revenue to the company, seem to not have any effect on
the development of products for the ﬁnal market.
6.2. Relational embeddedness and the position of the ﬁrm in the SCoI
We predicted (H3) a moderating and positive effect of rela-
tional embeddedness on the linkage between purchasing R&D and
the development of new products, and we found evidence of this.
The higher the relational embeddedness, the greater is the beneﬁt
coming from external knowledge acquisition. Prior literature ar-
gued that a high level of relational embeddedness brings a high
level of information richness (Goerzen, 2007; Wu, 2008). This
result shows that purchasing R&D services (or other kinds of R&D
commodities) yields greater potential for NPD under the condition
of a high level of relational embeddedness. This ﬁnding may be
interpreted as follows. The information richness that a company
gets from its innovation network positively inﬂuences its knowl-
edge absorptive capacity, and increases the opportunities for
learning and for developing the skills in managing the NPD pro-
cess. In other words, the ﬁrm, thanks to its relational embedded-
ness, better capitalizes on the knowledge coming from purchasing
R&D.
We predicted (H4) a negative effect of relational embeddedness
on the linkage between selling R&D and new products. We found a
signiﬁcant and negative effect of the product variable (R&D sell-
ingRelational_Emb), and because the main effect of the variable
R&D selling revealed to be not signiﬁcant we interpret the result asan interaction effect. This result demonstrates that selling R&D
services (or other kind of R&D commodities) yields lower potential
for NPD under the condition of a high level of relational em-
beddedness. To interpret this ﬁnding we need to go back to the
idea of ﬁrm positioning along the SCoI. Indeed, prior research tells
us that the information richness from the innovation network
positively affects the performance of the ﬁrm due to the organi-
zational experience coming from routines, organizational learning,
the reduction of intra-network asymmetries, and the increase in
trust (Gulati, 1995; Koka and Prescott, 2002; Malik, 2012). How-
ever, with the main business of R&D suppliers being the devel-
opment and marketing of R&D commodities, the information
richness positively inﬂuences the outcomes of these activities,
thus damagingly conditioning the ﬁrm’s propensity in developing
new products for the ﬁnal consumer market.
When looking at the overall ﬁndings, we can draw the fol-
lowing conclusions about relational embeddedness and NPD pro-
cess. Advantages of relational embeddedness have to be inter-
preted in the light of the position of the ﬁrm along the SCoI.
Speciﬁcally, managers of downstream companies should consider
that relational embeddedness in the innovation network brings
paybacks in their SCoI practices. Analogously, managers of up-
stream companies should consider that relational embeddedness
enforces their core business and their position in the SCoI. This, in
turns, brings drawbacks in their SCoI practices, in terms of their
propensity to develop products for the ﬁnal market.
Our ﬁndings bring anecdotal evidence of the existence of the
SCoI and of the phenomenon of ﬁrms’ positioning along it, at least
in the biopharmaceutical context. This calls for a number of issues
still to be explored in the supply chain management stream of
literature, which studies different kinds of relationships with
suppliers and buyers for NPD. The results of our study suggest that
when considering the knowledge ﬂow, different actors play the
role of buyer and supplier (of knowledge), rather than just the
buyers and suppliers belonging to the material ﬂow supply chain.
Studying this ﬂow and these special supply chain relationships
becomes crucial in NPD process.
Finally, the research ﬁndings bring the following managerial
implication. Our results show that both R&D purchasing/selling
and network characteristics inﬂuence the ability of the ﬁrm to
exploit external and internal knowledge to enhance innovation.
However, there are important differences between these two
concepts. R&D purchasing/selling activities concern a set of deci-
sions that can be directly controlled by the ﬁrms, since managers
contract with suppliers and buyers to buy or sell R&D commod-
ities. Conversely, the characteristics of the network are not entirely
under the ﬁrm's control. Indeed, the existence of cliques mainly
depends on external decisions (the company cannot decide whe-
ther or not its partners are connected to each others, thus com-
posing a clique). The effectiveness of managers’ decisions regard-
ing the purchase or selling of R&D commodities on NPD success
partially depends on exogenous factors. Managers undergo their
network structure characteristics (e.g. cliques), and thus have to
make their SCoI decisions according to these.
6.3. Limitations and further research
The results and the contribution of this study should be con-
sidered in light of its limitations. First, the data analysis is cross-
section and not longitudinal; the dependent variable is the sum of
three years and is not year-speciﬁc.
Secondly, because the intention is to analyse the supply chain
of innovation, this study focuses on the biopharmaceutical in-
dustry (traditionally involved in innovation processes) and ex-
cludes other types of industries. Although this approach is ap-
propriate, it would be unwise to generalize the ﬁndings too
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national diversity, being related to culture, might inﬂuence in-
novation attitudes, a control variable such as nationality might
have helped to improve the results.
Thirdly, we built on research on social capital theory to con-
sider how the position of the ﬁrm within the network of innova-
tion may affect relational embeddedness, and how information
richness originating from it inﬂuences supply chain relationships'
effectiveness. However, social capital is a multidimensional con-
struct that yields different information beneﬁts, not only in the
form of information richness, but also in terms of information
volume and information diversity (Koka and Prescott, 2002). A
complete comprehension of the moderating impact of network
social capital into the linkage between supply chain practices and
NPD would have required taking into account a number of net-
work characteristics other than cliques, such as number of part-
ners, partners of partners, structure holes, and so on.
Future research should be directed towards exploring and
evaluating the inﬂuence of SCoI and relational embeddedness on
companies' propensity in innovation, rather than just on devel-
oping new products. In fact, NPD is just one dimension of in-
novation performance, and researchers often capture innovation
performance through different innovation outcomes (e.g. number
of developed patents). Future research should thus be oriented to
explore the effect of positioning along the SCoI, and of the in-
novation network on different innovation performance. We think
that very interesting results could be revealed. Indeed, we showed
that positioning upstream in the SCoI tends to decrease the ﬁrm's
NPD propensity (this because we considered the number of new
products for the ﬁnal market, e.g. marketable drugs). If instead we
had considered the number of patents, or the number of techno-
logical platforms, or the number of test assays, we probably would
have discovered that positioning upstream tends to increase the
ﬁrm's innovation performance. The same considerations hold for
downstream positioning. Further study of this issue could bring
very interesting implications for R&D supply chain managers.
Also, further research in this ﬁeld should be directed towards
investigating whether purchasing and/or selling different kinds of
R&D commodities (as the object of the commercial R&D transac-
tion) differently affects the NPD process. For example, is there any
difference in purchasing patent licenses or research services? We
know, for instance, that purchasing a research service surely re-
quires a more intense integration with the supplier than pur-
chasing a license. Does this difference inﬂuence the way in which
the two R&D commodities affect the NPD process? Exploring this
issue could bring very interesting insights to innovation managers
in charge of supplying and selling R&D commodities.
However, overall this study opens new frontiers for supply
chain management researchers. Besides adopting the SCoI per-
spective for studying supply chain relationships in NPD, they
might use the SCoI as a new test bed where they can explore and
study the same topics that they usually treat in traditional (ma-
terial ﬂow) supply chains. For example, classical topics such as
single versus multiple sourcing (Burke et al., 2007), supply chain
coordination or strategic purchasing decisions (Ogden et al., 2007)
could be investigated for the supply chain of innovation.References
Adler, P.S., Kwon, S.W., 2002. Social capital: prospects for a new concept. Acad.
Manag. Rev. 27 (1), 17–40.
Ahuja, G., 2000. Collaboration networks, structural holes, and innovation: a long-
itudinal study. Adm. Sci. Q. 45 (3), 425–455.
Bae, J., Gargiulo, M., 2004. Partner substitutability, alliance network structure, and
ﬁrm proﬁtability in the telecommunications industry. Acad. Manag. J. 47,
843–859.Birch, K., 2008. Alliance-driven governance: applying a global commodity chains
approach to the U.K. biotechnology industry. Econ. Geogr. 84, 83–103.
Borgatti, S.P., Everett, M.G., Freeman, L.C., 2002. Ucinet 6 for Windows. Analytic
Technologies, Harvard, MA.
Burke, G.J., Carrillo, J.E., Vakharia, A.J., 2007. Single versus multiple supplier sour-
cing strategies. Eur. J. Oper. Res. 182 (1), 95–112.
Burt, R.S., 1998. The Network Structure of Social Capital. University of Chicago,
Chicago.
Chesbrough, H., 2003. Open Innovation, Cambridge, MA. Harvard University Press.
Chiaroni, D., Chiesa, V., Frattini, F., 2010. Unravelling the process from closed to
open innovation: evidence from mature, asset-intensive industries. R&D
Manag. 40 (3), 222–245.
Chiesa, V., Toletti, G., 2004. Network of collaborations for innovation: the case of
biotechnology. Technol. Anal. Strateg. Manag. 16 (11), 73–96.
Christopher, M.G., 1992. Logistics and Supply Chain Management. Pitman Pub-
lishing, London, UK.
Cohen, W.M., Levinthal, D., 1990. Absorptive capacity: a new perspective on
learning and innovation. Adm. Sci. Q. 35 (1), 128–152.
Coleman, J.S., 1988. Social capital in the creation of human capital. Am. J. Sociol. 94,
95–120.
Danese, P., Romano, P., 2013. The moderating role of supply network structure on
the customer integration-efﬁciency relationship. Int. J. Oper. Prod. Manag. 33
(4), 372–393.
DeCarolis, D.M., Deeds, D.L., 1999. The impact of stocks and ﬂows of organizational
knowledge on ﬁrm performance: an empirical investigation of the bio-
technology industry. Strateg. Manag. J. 20 (10), 953–968.
Ettlie, J.E., Pavlou, P.A., 2006. Technology-based new product development part-
nerships. Decis. Sci. 37 (2), 117–147.
Flynn, B.B., Huo, B., Zhao, X., 2010. The impact of supply chain integration on per-
formance: a contingency and conﬁguration approach. J. Oper. Manag. 28 (1),
58–71.
Goerzen, A., 2007. Alliance networks and ﬁrm performance: the impact of repeated
partnerships. Strateg. Manag. J. 28 (5), 487–509.
Granovetter, M., 1992. Problems of explanation in economic sociology. In: Nohria,
N., Eccles, R. (Eds.), Networks and Organizations: Structure, Form and Action.
Harvard Business School Press, Boston, MA, pp. 25–56.
Gujarati, D.N., 1995. Basic Econometrics, third ed. McGraw-Hill Inc., New York.
Gulati, R., 1995. Does familiarity breed trust? The implications of repeated ties for
contractual choice in alliances. Acad. Manag. J. 38 (1), 85–112.
Harland, C.M., 1996. Supply chain management: relationships, chains and net-
works. Br. J. Manag. 7 (s1), S63–S80.
Hausman, J., Hall, B., Griliches, Z., 1984. Econometric models for count data with an
application to the patents-R&D relationship. Econometrica 52, 909–938.
Homburg, C., Stock, R.M., 2004. The link between sales people's job satisfaction and
customer satisfaction in a business-to-business context: a dyadic analysis. J.
Acad. Market. Sci. 32 (2), 144–158.
Humphreys, P., Huang, G., Cadden, T., McIvor, R., 2007. Integrating design metrics
within the early supplier selection process. J. Purch. Supply Manag. 13 (1),
42–52.
Jaccard, J., Turrisi, R., 2003. Interaction Effects in Multiple Regression, third ed. Sage,
Thousand Oaks, CA.
Jean, R.J., Kim, D., Sinkovics, R.R., 2012. Drivers and performance outcomes of
supplier innovation generation in customer-supplier relationships: the role of
power-dependence. Decis. Sci. 43 (6), 1003–1038.
Johnsen, T.E., 2009. Supplier involvement in new product development and in-
novation: taking stock and looking to the future. J. Purch. Supply Manag. 15 (3),
187–197.
Koka, B., Prescott, J.E., 2002. Strategic alliances as social capital: a multidimensional
view. Strateg. Manag. J. 23 (9), 795–816.
Koufteros, X., Edwin Cheng, T.C., Lai, K., 2007. “Black-box” and “gray-box” supplier
integration in NPD: antecedents, consequences and the moderating role of ﬁrm
size. J. Oper. Manag. 25 (4), 847–870.
Koufteros, X., Vonderembse, M., Jayaram, J., 2005. Internal and external integration
for product development: the contingency effects of uncertainty, equivocality,
and platform strategy. Decis. Sci. 36 (1), 97–133.
Krause, D.R., Handﬁeld, R.B., Tyler, B.B., 2007. The relationships between supplier
development, commitment, social capital accumulation and performance im-
provement. J. Oper. Manag. 25 (2), 528–545.
Laursen, K., Salter, A., 2006. Open for innovation: the role of openness in explaining
innovation performance among U.K. manufacturing ﬁrms. Strateg. Manag. J. 27
(2), 131–150.
Malik, T., 2012. Disparate association between alliance social capital and the global
pharmaceutical ﬁrm's performance. Int. Bus. Rev. 21 (6), 1017–1028.
Mazzola, E., Bruccoleri, M., Perrone, G., 2012. The effect of inbound, outbound and
coupled innovation on performance. Int. J. Innov. Manag. 16 (6), 1240008 27 pp.
Mazzola, E., Perrone, G., Kamuriwo, D.S., 2015. Network embeddedness and new
product development in the biopharmaceutical industry: the moderating role
of open innovation ﬂow. Int. J. Prod. Econ. 160, 106–119.
Meehan, J., Bryde, D.J., 2014. Procuring sustainably in social housing: the role of
social capital. J. Purch. Supply Manag. 20 (2), 74–81.
Menguc, B., Auh, S., Yannopoulos, P., 2014. Customer and supplier involvement in
design: The moderating role of incremental and radical innovation capability. J.
Product Innov. Manag. 31 (2), 313–328.
Mishra, A.A., Shah, R., 2009. In union lies strength: collaborative competence in
new product development and its performance effects. J. Oper. Manag. 27 (4),
324–338.
E. Mazzola et al. / Journal of Purchasing & Supply Management 21 (2015) 273–284284Mol, M.J., 2003. Purchasing’s strategic relevance. J. Purch. Supply Manag. 9 (1),
43–50.
Moran, P., 2005. Structural versus relational embeddedness: social capital and
managerial performance. Strateg. Manag. J. 26, 1129–1151.
Narayana, S.A., Kumar Pati, R., Vrat, P., 2014. Managerial research on the pharma-
ceutical supply chain – a critical review and some insights for future directions.
J. Purch. Supply Manag. 20 (1), 18–40.
Ogden, J.A., Rossetti, C.L., Hendrick, T.E., 2007. An exploratory cross-country com-
parison of strategic purchasing. J. Purch. Supply Manag. 13 (1), 2–16.
Pérez-Luño, A., Medina, C.C., Lavado, A.C., Rodríguez, G.C., 2011. How social capital
and knowledge affect innovation. J. Bus. Res. 64 (12), 1369–1376.
Petersen, K.J., Handﬁeld, R.B., Ragatz, G.L., 2005. Supplier integration into new
product development: coordinating product, process and supply chain design. J.
Oper. Manag. 23 (3/4), 371–388.
Phelps, C., 2003. Technological exploration: a longitudinal study of the role of
combinatory search and social capital in alliance networks, Unpublished Dis-
sertation. New York University.
Phelps, C.C., 2010. A longitudinal study of the inﬂuence of alliance network struc-
ture and composition on ﬁrm exploratory innovation. Acad. Manag. J. 53 (4),
890–913.
Pilkington, A., 1999. Strategic alliance and dependency in design and manufacture:
the Rover-Honda case. Int. J. Oper. Prod. Manag. 19 (5/6), 460–474.
Pisano, G., 1991. The governance of innovation: vertical integration and colla-
borative arrangements in the biotechnology industry. Res. Policy 20 (3),
237–250.
Powell, W.W., Koput, K.W., Smith-Doerr, L., 1996. Interorganizational collaboration
and the locus of innovation: networks of learning in biotechnology. Adm. Sci. Q.
41 (1), 116–145.
Ragatz, G.L., Handﬁeld, R.B., Petersen, K.J., 2002. Beneﬁts associated with supplier
integration into new product development under conditions of technological
uncertainty. J. Bus. Res. 55, 389–400.
Rosenkopf, L., Schilling, M.A., 2007. Comparing alliance network structure across
industries: observations and explanations. Strateg. Entrepreneurship J. 1 (3–4),
191–209.
Rothaermel, F.T., Deeds, D.L., 2004. Exploration and exploitation alliances in bio-
technology: a system of new product development. Strateg. Manag. J. 25 (3),
201–221.
Rowley, T.J., Greve, H.R., Hayagreeva, R., Baum, J.A.C., 2005. Time to break up: social
and instrumental antecedents of ﬁrm exits from exchange cliques. Acad.
Manag. J. 48 (3), 499–520.
Sabatier, V., Mangematin, V., Rousselle, T., 2010. Orchestrating networks in the
biopharmaceutical industry: small hub ﬁrms can do it. Prod. Plan. Control 21
(2), 218–228.
Salman, N., Saives, A.L., 2005. Indirect networks: an intangible resource for bio-
technology innovation. R&D Manag. 35 (2), 203–215.
Salvador, F., Villena, V.H., 2013. Supplier integration and NPD outcomes: conditional
moderation effects of modular design competence. J. Supply Chain Manag. 49(1), 87–113.
Schilling, M., Phelps, C., 2007. Interﬁrm collaboration networks and knowledge
creation: the impact of large scale network structure on ﬁrm innovation.
Manag. Sci. 53 (7), 1113–1126.
Soh, P.H., 2003. The role of networking alliances in information acquisition and its
implications for new product performance. J. Bus. Ventur. 18 (6), 727–744.
Song, L.Z., Song, M., Di Benedetto, C.A., 2011. Resources, supplier investment, pro-
duct launch advantages, and ﬁrst product performance. J. Oper. Manag. 29 (1/
2), 86–104.
Song, M., Benedetto, A.D., 2008. Supplier's involvement and success of radical new
product development in new ventures. J. Oper. Manag. 26 (1), 1–22.
Stevens, J., 1992. Applied Multivariate Statistics for the Social Sciences. Lawrence
Erlbaum Associates, Hillsdale, NJ.
Stuart, T.E., Ozdemir, S., Ding, W., 2007. Vertical alliance networks: the case of
university–biotechnology–pharmaceutical alliance chains. Res. Policy 36 (4),
477–498.
Swink, M., Narasimhan, R., Wang, C., 2007. Managing beyond the factory walls:
effects of four types of strategic integration on manufacturing plant perfor-
mance. J. Oper. Manag. 25 (1), 148–164.
Teece, D.J., 1992. Competition, cooperation, and innovation: organizational ar-
rangements for regimes of rapid technological progress. J. Econ. Behav. Org. 18,
1–25.
Tsai, K.H., Wang, J.C., 2009. External technology sourcing and innovation perfor-
mance in LMT sectors: an analysis based on the Taiwanese technological in-
novation survey. Res. Policy 38 (3), 518–526.
Twigg, D., 1998. Managing product development within a design chain. Int. J. Oper.
Prod. Manag. 18 (5), 508–524.
Un, C.A., Cazurra, A.C., Asakawa, K., 2010. R&D collaborations and product innova-
tion. J. Product Innov. Manag. 27 (5), 673–689.
Uzzi, B., 1996. The sources and consequences of embeddedness for the economic
performance of organizations: the network effect. Am. Sociol. Rev. 61, 674–698.
Vanhaverbeke, W., Gilsing, V., Beerkens, B., Duysters, G., 2009. The role of alliance
network redundancy in the creation of core and non-core technologies: a local
action approach. J. Manag. Stud. 46 (2), 215–244.
Wasserman, S., Faust, K., 1994. Social Network Analysis: Methods and Applications.
Cambridge University Press, New York.
West, J., Bogers, M., 2013. Leveraging external sources of innovation: a review of
research on open innovation. J. Product Innov. Manag. 〈http://dx.doi.org/10.
1111/jpim.12125.
West, J., Salter, A., Vanhaverbeke, W., Chesbrough, H., 2014. Open innovation: the
next decade. Res. Policy 43 (5), 805–811.
Wu, W.P., 2008. Dimensions of social capital and ﬁrm competitiveness improve-
ment: the mediating role of information sharing. J. Manag. Stud. 45 (1),
122–146.
